ChromaDex Future Growth
Future criteria checks 4/6
ChromaDex is forecast to grow earnings and revenue by 93.2% and 15.4% per annum respectively while EPS is expected to grow by 101.2% per annum.
Key information
93.2%
Earnings growth rate
101.2%
EPS growth rate
Life Sciences earnings growth | 21.7% |
Revenue growth rate | 15.4% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 09 Apr 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 138 | 9 | 13 | 14 | 1 |
12/31/2025 | 114 | 4 | 9 | 14 | 4 |
12/31/2024 | 97 | -2 | 1 | 6 | 5 |
12/31/2023 | 84 | -5 | 7 | 7 | N/A |
9/30/2023 | 83 | -6 | 6 | 6 | N/A |
6/30/2023 | 81 | -6 | 2 | 2 | N/A |
3/31/2023 | 77 | -11 | -6 | -5 | N/A |
12/31/2022 | 72 | -17 | -15 | -15 | N/A |
9/30/2022 | 69 | -20 | -20 | -20 | N/A |
6/30/2022 | 69 | -28 | -22 | -22 | N/A |
3/31/2022 | 70 | -27 | -26 | -26 | N/A |
12/31/2021 | 67 | -27 | -25 | -24 | N/A |
9/30/2021 | 65 | -28 | -20 | -19 | N/A |
6/30/2021 | 62 | -23 | -17 | -17 | N/A |
3/31/2021 | 60 | -21 | -11 | -11 | N/A |
12/31/2020 | 59 | -20 | -11 | -11 | N/A |
9/30/2020 | 57 | -23 | -12 | -11 | N/A |
6/30/2020 | 55 | -26 | -16 | -15 | N/A |
3/31/2020 | 51 | -30 | -23 | -23 | N/A |
12/31/2019 | 46 | -32 | -21 | -20 | N/A |
9/30/2019 | 42 | -32 | -26 | -25 | N/A |
6/30/2019 | 38 | -33 | -23 | -22 | N/A |
3/31/2019 | 35 | -33 | -22 | -20 | N/A |
12/31/2018 | 32 | -33 | -22 | -21 | N/A |
9/30/2018 | 30 | -34 | -21 | -20 | N/A |
6/30/2018 | 28 | -29 | -17 | -15 | N/A |
3/31/2018 | 24 | -23 | -15 | -14 | N/A |
12/30/2017 | 21 | -17 | N/A | -10 | N/A |
9/30/2017 | 18 | -10 | N/A | -6 | N/A |
7/1/2017 | 16 | -8 | N/A | -6 | N/A |
4/1/2017 | 18 | -6 | N/A | 0 | N/A |
12/31/2016 | 22 | -4 | N/A | -3 | N/A |
10/1/2016 | 22 | -3 | N/A | -4 | N/A |
7/2/2016 | 24 | -2 | N/A | -5 | N/A |
4/2/2016 | 24 | -1 | N/A | -4 | N/A |
1/2/2016 | 18 | -3 | N/A | -2 | N/A |
10/3/2015 | 22 | -3 | N/A | -2 | N/A |
7/4/2015 | 20 | -3 | N/A | -1 | N/A |
4/4/2015 | 18 | -5 | N/A | -2 | N/A |
1/3/2015 | 15 | -5 | N/A | -3 | N/A |
9/27/2014 | 13 | -5 | N/A | -4 | N/A |
6/28/2014 | 12 | -5 | N/A | -4 | N/A |
3/29/2014 | 11 | -5 | N/A | -5 | N/A |
12/28/2013 | 10 | -4 | N/A | -4 | N/A |
9/28/2013 | 11 | -5 | N/A | -3 | N/A |
6/29/2013 | 12 | -6 | N/A | -4 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: OCD1 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.6%).
Earnings vs Market: OCD1 is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: OCD1 is expected to become profitable in the next 3 years.
Revenue vs Market: OCD1's revenue (15.4% per year) is forecast to grow faster than the German market (5.5% per year).
High Growth Revenue: OCD1's revenue (15.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if OCD1's Return on Equity is forecast to be high in 3 years time